

Cell Line Data Sheet for Rh30

Disease: Rhabdomyosarcoma
Histology Subtype: Alveolar
Phase of Therapy: Diagnosis
Treatment: None
Gender: Male
Age at diagnosis: 17 years
Race: N/A
Age at sample collection: N/A
Source of Culture: Bone Marrow
Primary Tumor Site: Posterior fossa
Date Established:

PAX-FKHR Status: Positive for translocation
p53 functionality: Functional
Karyotype:
Modal No:

R-IC50 (DIMSCAN*):	<u>Vincristine (ng/ml)</u>	<u>Melphalan (µg/ml)</u>	<u>Etoposide (ng/ml)</u>	<u>Rapamycin (ng/ml)</u>
*see reference 1	0.30 ± 0.07	2.05 ± 0.29	0.19 ± 0.03	0.73 ± 0.13

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 35 hours
Growth Properties: Elongated cells and round cells, adherent with small population of suspended cells

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes: Positive for MyoD1 and myogenin

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



Cell Line Data Sheet for RH30

References:

1. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatric Blood Cancer* 56: 239-249, 2011. PubMed ID: 20922763
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>

SEE NCI Pediatric Preclinical Testing Program references.

2. Petak, I., Douglas, L., Tillman, D.M., Vernes, R., Houghton, J.A. (2000). Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. *Clin Cancer Res* 6, 4119-27. PM:11051265
<https://clincancerres.aacrjournals.org/content/6/10/4119.long>
3. Rodriguez-Perales, S., Martinez-Ramirez, A., de Andres, S.A., Valle, L., Urioste, M., Benitez, J., Cigudosa, J.C. (2004). Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. *Cancer Genet Cytogenet* 148, 35-43. PM:14697639
<https://www.sciencedirect.com/science/article/pii/S0165460803002164?via%3Dihub>



Cell Line Data Sheet for RH30

Cell Line Name: RH30

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)